BCM
GBT

BlueCrest Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

BlueCrest Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,801
Closed -$258K – 1562
2018
Q3 		$258K Buy
6,801
+1
+0% +$44 0.01% 1123
2018
Q2 		$307K Buy
+6,800
New +$310K 0.01% 1086

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's GBT Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2018, closing a stake of 6,801 shares — an estimated $258K sold.

BlueCrest Capital Management first reported a position in GBT in Q2 2018 and held it in 2 quarters. The position peaked at $307K in Q2 2018. 190 funds tracked by Wall St. Rank hold GBT as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 6,801 Global Blood Therapeutics, Inc. shares in Q4 2018, an estimated $258K.
  • BlueCrest Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Global Blood Therapeutics, Inc. position peaked at $307K in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.